• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).

作者信息

van Breukelen F J, Bijvoet O L, van Oosterom A T

出版信息

Lancet. 1979 Apr 14;1(8120):803-5. doi: 10.1016/s0140-6736(79)91319-9.

DOI:10.1016/s0140-6736(79)91319-9
PMID:86043
Abstract

14 patients with osteolytic bone disease due to breast cancer or myeloma, 7 of whom had hypercalcaemia, received oral treatment with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Serum-calcium dropped to low normal values in all 14 patients, accompanied by a decrease in urine calcium and hydroxyproline excretion-rate. The results show that A.P.D. may inhibit tumour-induced osteolysis.

摘要

相似文献

1
Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).
Lancet. 1979 Apr 14;1(8120):803-5. doi: 10.1016/s0140-6736(79)91319-9.
2
[Treatment of hypercalcemia in osteolytic metastases with oral amino-hydroxypropylidene-diphosphonate].
Presse Med. 1984 Feb 25;13(8):483-6.
3
[Role of diphosphonates in the therapy of osteolysis and malignant hypercalcemia].
Rev Rhum Mal Osteoartic. 1984 Dec 15;51(11):663-6.
4
3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer.3-（氨基-1,1-羟基亚丙基）双膦酸盐（APD）治疗乳腺癌高钙血症。
Br J Cancer. 1987 Oct;56(4):465-9. doi: 10.1038/bjc.1987.225.
5
Osteolytic bone metastases in breast carcinoma pathogenesis, morbidity and bisphosphonate treatment.乳腺癌溶骨性骨转移的发病机制、发病率及双膦酸盐治疗
Eur J Cancer Clin Oncol. 1986 Apr;22(4):493-500. doi: 10.1016/0277-5379(86)90117-3.
6
Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy.帕米膦酸盐对骨髓瘤骨骼病变的影响。第1部分：帕米膦酸盐治疗前12个月的结果。
Acta Pol Pharm. 2000 Nov;57 Suppl:113-6.
7
The use of dichloromethylene diphosphonate for the management of hypercalcaemia in multiple myeloma.
Br J Haematol. 1983 May;54(1):121-32. doi: 10.1111/j.1365-2141.1983.tb02074.x.
8
Treatment of tumor-induced osteolysis by APD.应用抗酒石酸酸性磷酸酶治疗肿瘤诱导的骨溶解。
Recent Results Cancer Res. 1989;116:54-66. doi: 10.1007/978-3-642-83668-8_5.
9
Use of bisphosphonates in cancer patients.
Cancer Treat Rev. 1996 Jul;22(4):265-87. doi: 10.1016/s0305-7372(96)90020-1.
10
[Bone targeting agents: bisphosphonates].[骨靶向剂：双膦酸盐]
Bull Cancer. 2013 Nov;100(11):1199-206. doi: 10.1684/bdc.2013.1840.

引用本文的文献

1
Atypical femoral fractures: a review of the literature.非典型股骨骨折：文献回顾。
Curr Osteoporos Rep. 2013 Sep;11(3):179-87. doi: 10.1007/s11914-013-0167-y.
2
Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversies.双膦酸盐类药物治疗骨质疏松症：对其贡献和争议的综述。
Skeletal Radiol. 2011 Sep;40(9):1191-6. doi: 10.1007/s00256-011-1164-9. Epub 2011 Aug 17.
3
Decrease of serum calcium concentration and lost influence of calcium on parathyroid hormone release in a patient with primary hyperparathyroidism after treatment with diphosphonates.
Calcif Tissue Int. 1993 Nov;53(5):301-3. doi: 10.1007/BF01351832.
4
Differential action of the bisphosphonates (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (Cl2MDP) on rat macrophage-mediated bone resorption in vitro.双膦酸盐（3-氨基-1-羟基亚丙基）-1,1-双膦酸盐（APD）和二氯亚甲基双膦酸二钠（Cl2MDP）对大鼠巨噬细胞介导的体外骨吸收的不同作用。
J Clin Invest. 1982 Nov;70(5):927-33. doi: 10.1172/jci110704.
5
Apposition and resorption of bone during oral treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).
Calcif Tissue Int. 1983 May;35(3):357-61. doi: 10.1007/BF02405058.
6
Structure-activity relationships of various bisphosphonates.各种双膦酸盐的构效关系。
Calcif Tissue Int. 1983;35(1):87-99. doi: 10.1007/BF02405012.
7
Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium.氨基羟丙基二膦酸盐治疗高钙血症的疗效：血清钙调节的观察
Calcif Tissue Int. 1982 Jul;34(4):321-7. doi: 10.1007/BF02411261.
8
Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) in rats.大鼠使用（3-氨基-1-羟基亚丙基）-1,1-二膦酸盐（APD）治疗期间骨与矿物质代谢的动力学研究
Calcif Tissue Int. 1980;32(2):145-57. doi: 10.1007/BF02408534.
9
The bisphosphonates HEBP and AHPrBP but not AHBP inhibit mineral mobilization and lysosomal enzyme release from mouse calvarial bones in tissue culture.
Experientia. 1984 Sep 15;40(9):965-7. doi: 10.1007/BF01946461.
10
Human parathyroid hormone 1-34-mediated hypercalcemia in a rat model, and its inhibition by dichloromethane diphosphonate.人甲状旁腺激素1-34介导的大鼠模型高钙血症及其二氯甲烷二膦酸盐抑制作用
Calcif Tissue Int. 1981;33(6):649-54. doi: 10.1007/BF02409503.